Larimar Therapeutics
Adrienne Clements-Egan has over 25 years of experience in scientific research and leadership roles. Adrienne has worked in various positions at Johnson & Johnson, including Principal Research Scientist and Associate Scientific Director, and at Janssen Biotherapeutics as a Scientific Director. Adrienne also has experience as a Medical Writer and a Yoga Instructor. Adrienne'smost recent role is as Senior Director, Bioanalytical Sciences at Janssen Inc., where they oversee a team of 40+ employees who provide bioanalytical solutions for biologic drug candidates. Starting from 2023, they will assume the role of Vice President, Bioanalytics & Developability at Larimar Therapeutics Inc.
Adrienne Clements-Egan received their Bachelor of Science degree in Biochemistry from the University of Nevada, Reno in 1995. Adrienne then pursued their Ph.D. in Biochemistry and Molecular Biophysics at the University of Pennsylvania from 1995-2001.
This person is not in any teams
Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.